See more : Emdoor Information CO.,LTD. (001314.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Avid Bioservices, Inc. (CDMO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avid Bioservices, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Horizon Bancorp, Inc. (HBNC) Income Statement Analysis – Financial Results
- Kolon Global Corporation (003075.KS) Income Statement Analysis – Financial Results
- Redwoods Acquisition Corp. (RWOD) Income Statement Analysis – Financial Results
- Alight, Inc. (ALIT) Income Statement Analysis – Financial Results
- Copperstone Resources AB (COPP-B.ST) Income Statement Analysis – Financial Results
Avid Bioservices, Inc. (CDMO)
About Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 139.91M | 149.27M | 119.60M | 95.87M | 59.70M | 53.60M | 53.62M | 57.63M | 44.69M | 26.78M | 22.40M | 21.68M | 15.23M | 13.49M | 27.94M | 18.15M | 6.09M | 3.71M | 3.19M | 4.96M | 3.31M | 3.92M | 3.77M | 979.00K | 1.00K | 100.00K | 500.00K | 300.00K | 3.10M | 100.00K |
Cost of Revenue | 132.59M | 117.79M | 82.95M | 66.56M | 55.77M | 46.38M | 56.55M | 38.26M | 22.97M | 15.59M | 13.11M | 12.60M | 10.15M | 7.30M | 8.72M | 9.06M | 4.80M | 3.30M | 3.30M | 4.40M | 2.21M | 2.86M | 0.00 | -412.00K | -516.00K | 3.50M | -700.00K | -300.00K | 0.00 | 1.00M |
Gross Profit | 7.32M | 31.48M | 36.65M | 29.31M | 3.93M | 7.22M | -2.92M | 19.37M | 21.72M | 11.19M | 9.29M | 9.09M | 5.08M | 6.20M | 19.23M | 9.09M | 1.29M | 412.00K | -104.00K | 558.00K | 1.10M | 1.06M | 3.77M | 1.39M | 517.00K | -3.40M | 1.20M | 600.00K | 3.10M | -900.00K |
Gross Profit Ratio | 5.23% | 21.09% | 30.64% | 30.57% | 6.59% | 13.48% | -5.45% | 33.61% | 48.61% | 41.78% | 41.48% | 41.91% | 33.35% | 45.92% | 68.81% | 50.06% | 21.16% | 11.11% | -3.26% | 11.25% | 33.25% | 27.06% | 100.00% | 142.08% | 51,700.00% | -3,400.00% | 240.00% | 200.00% | 100.00% | -900.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.30M | 59.53M | 43.00M | 27.72M | 24.31M | 35.69M | 29.46M | 24.66M | 18.42M | 18.28M | 15.88M | 12.42M | 11.16M | 9.67M | 8.74M | 13.51M | 7.38M | 8.08M | 8.80M | 7.60M | 30.00M | 1.70M | 0.00 |
General & Administrative | 25.20M | 27.18M | 20.63M | 16.76M | 14.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
Selling & Marketing | 800.00K | 700.00K | 600.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 19.33M | 18.55M | 18.69M | 17.27M | 13.13M | 11.46M | 11.42M | 8.18M | 6.98M | 7.15M | 6.45M | 6.56M | 5.10M | 4.23M | 2.99M | 2.48M | 3.81M | 4.24M | 6.20M | 4.50M | 3.30M | 900.00K | 700.00K |
Other Expenses | 1.00 | 1.00M | -81.00K | 133.00K | 355.00K | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
Operating Expenses | 26.00M | 27.88M | 21.23M | 17.06M | 14.52M | 12.85M | 16.46M | 47.63M | 78.08M | 61.69M | 45.00M | 37.44M | 47.15M | 40.88M | 32.84M | 25.40M | 25.43M | 22.32M | 18.98M | 16.26M | 13.90M | 11.73M | 15.98M | 11.60M | 12.83M | 16.00M | 12.80M | 33.60M | 2.80M | 900.00K |
Cost & Expenses | 158.59M | 145.67M | 104.18M | 83.63M | 70.29M | 59.23M | 73.00M | 85.89M | 101.05M | 77.28M | 58.11M | 50.04M | 57.30M | 48.18M | 41.56M | 34.47M | 30.23M | 25.62M | 22.28M | 20.66M | 16.11M | 14.59M | 15.98M | 11.19M | 12.31M | 19.50M | 12.10M | 33.30M | 2.80M | 1.90M |
Interest Income | 0.00 | 2.60M | 2.68M | 133.00K | 474.00K | 282.00K | 102.00K | 108.00K | 722.00K | 142.00K | 349.00K | 322.00K | 41.00K | 1.05M | 116.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 4.34M | 2.60M | 2.68M | 1.16M | 8.00K | 11.00K | 27.00K | 7.00K | 14.00K | 1.00K | 5.00K | 54.00K | 90.00K | 516.00K | 997.00K | 408.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 11.11M | 7.21M | 4.48M | 3.45M | 3.09M | 2.75M | 2.56M | 2.46M | 1.54M | 1.04M | 986.00K | 1.09M | 908.00K | 652.00K | 1.12M | 503.00K | 486.00K | 866.00K | 415.00K | 325.00K | 2.19M | 1.38M | 424.00K | 412.00K | 516.00K | 1.00M | 700.00K | 300.00K | 200.00K | 200.00K |
EBITDA | -11.48M | 10.91M | 19.90M | 15.70M | -7.38M | -2.59M | -16.82M | 3.76M | 5.02M | -49.32M | -34.37M | -28.64M | -41.12M | -32.98M | -13.05M | -15.61M | -23.65M | -21.04M | -18.67M | -15.38M | -10.61M | -9.29M | -11.79M | -9.80M | -11.79M | -18.50M | -11.30M | -32.90M | 500.00K | -1.60M |
EBITDA Ratio | -8.21% | 3.08% | 12.83% | 12.91% | -17.14% | -10.49% | -35.95% | -48.85% | -121.07% | -184.15% | -153.44% | -129.27% | -276.18% | -257.09% | -44.72% | -87.12% | -388.22% | -567.53% | -623.14% | -310.12% | -320.19% | -236.90% | -313.17% | -1,000.20% | -960,400.00% | -18,800.00% | -2,180.00% | -10,900.00% | 22.58% | 3,400.00% |
Operating Income | -18.68M | -2.61M | 10.86M | 8.92M | -10.59M | -5.62M | -20.64M | -28.26M | -56.36M | -50.50M | -35.71M | -28.35M | -42.07M | -34.69M | -13.61M | -16.32M | -24.14M | -21.91M | -19.08M | -15.70M | -12.80M | -10.67M | -12.22M | -10.21M | -12.31M | -19.40M | -11.60M | -33.00M | 300.00K | -1.80M |
Operating Income Ratio | -13.35% | -1.75% | 9.08% | 9.31% | -17.73% | -10.49% | -38.49% | -49.04% | -126.12% | -188.56% | -159.39% | -130.76% | -276.18% | -257.09% | -48.72% | -89.89% | -396.19% | -590.88% | -597.65% | -316.68% | -386.12% | -272.12% | -324.43% | -1,043.21% | -1,231,000.00% | -19,400.00% | -2,320.00% | -11,000.00% | 9.68% | -1,800.00% |
Total Other Income/Expenses | -8.25M | -2.01M | -2.76M | -1.03M | 119.00K | 282.00K | 75.00K | 101.00K | 708.00K | 141.00K | 344.00K | -1.43M | -49.00K | 536.00K | 13.61M | 16.32M | 964.00K | 1.11M | 2.02M | 252.00K | -1.55M | 0.00 | 0.00 | -9.00K | -2.19M | 499.00K | 0.00 | 0.00 | -200.00K | -5.00M |
Income Before Tax | -26.93M | 2.00M | 12.66M | 11.21M | -10.47M | -5.34M | -20.56M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -34,151.00B | -34,151.00B | -14,494.00B | -16,524.00B | 0.00 | 0.00 | -17.85M | 0.00 | -14.35M | 0.00 | 0.00 | -10.22M | -14.50M | -19.00M | 0.00 | 0.00 | 100.00K | -6.80M |
Income Before Tax Ratio | -19.25% | 1.34% | 10.59% | 11.70% | -17.53% | -9.96% | -38.35% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -224,190,901.33% | -253,120,367.63% | -51,869,877.97% | -91,036,306.54% | 0.00% | 0.00% | -559.16% | 0.00% | -432.86% | 0.00% | 0.00% | -1,044.13% | -1,450,000.00% | -19,000.00% | 0.00% | 0.00% | 3.23% | -6,800.00% |
Income Tax Expense | 113.83M | 1.44M | -115.01M | -2.29M | -3.21M | -284.00K | -1.29M | -2.36M | 722.00K | 142.00K | 349.00K | -1.03M | 536.00B | 536.00B | -881.00B | -208.00B | -964.00K | -1.11M | -2.02M | -252.00K | 0.00 | 889.00K | -500.00K | -678.00K | 2.20M | 100.00K | 200.00K | 200.00K | 0.00 | 5.10M |
Net Income | -140.75M | 560.00K | 127.67M | 11.21M | -7.26M | -4.22M | -21.81M | -28.16M | -55.65M | -50.36M | -35.36M | -29.78M | -42.12M | -34.15M | -14.49M | -16.52M | -23.18M | -20.80M | -17.06M | -15.45M | -14.35M | -11.56M | -11.72M | -9.54M | -14.51M | -19.50M | -11.80M | -33.20M | 300.00K | -6.90M |
Net Income Ratio | -100.60% | 0.38% | 106.75% | 11.70% | -12.15% | -7.86% | -40.68% | -48.86% | -124.54% | -188.04% | -157.86% | -137.34% | -276.50% | -253.12% | -51.87% | -91.04% | -380.37% | -560.84% | -534.33% | -311.60% | -432.86% | -294.80% | -311.15% | -973.95% | -1,451,400.00% | -19,500.00% | -2,360.00% | -11,066.67% | 9.68% | -6,900.00% |
EPS | -2.23 | 0.01 | 2.08 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
EPS Diluted | -2.23 | 0.01 | 1.81 | 0.06 | -0.13 | -0.08 | -0.46 | -0.76 | -1.80 | -1.93 | -1.53 | -1.73 | -3.53 | -3.93 | -2.07 | -2.56 | -3.67 | -3.79 | -3.55 | -3.73 | -3.74 | -3.47 | -3.92 | -3.51 | -6.26 | -10.32 | -13.35 | -54.25 | 0.70 | -15.40 |
Weighted Avg Shares Out | 63.20M | 62.27M | 61.48M | 58.22M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
Weighted Avg Shares Out (Dil) | 63.20M | 63.78M | 70.47M | 59.43M | 56.33M | 55.98M | 47.06M | 37.11M | 30.90M | 26.08M | 23.08M | 17.20M | 11.94M | 8.70M | 7.01M | 6.46M | 6.32M | 5.49M | 4.81M | 4.14M | 3.84M | 3.33M | 2.99M | 2.72M | 2.32M | 1.89M | 884.22K | 611.98K | 428.57K | 448.05K |
Avid Bioservices, Inc. (CDMO) Q2 2024 Earnings Call Transcript
Avid Bioservices (CDMO) Reports Q2 Loss, Lags Revenue Estimates
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
Down -22.27% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
From laggards to leaders: Small caps on the rise
It's Small Stocks' Time To Rally — Analysts Like These 11 Best
Avid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility
Source: https://incomestatements.info
Category: Stock Reports